Inactivated Vaccines Market Revenue to Attain USD 71.01 Bn by 2033

01 Aug 2025

Share :

Table of Content

1. Inactivated Vaccines Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Insights 4. Regional Insights 5. Inactivated Vaccines Market Coverage 6. Inactivated Vaccines Market Players

Inactivated Vaccines Market Revenue and Trends 2025 to 2033

The global inactivated vaccines market size revenue was valued at USD 45.44 billion in 2025 and is expected to attain around USD 71.01 billion by 2033, growing at a CAGR of 5.74% during forecast period. This market is growing due to the growing global demand for safe, effective immunization. Rising government immunization programs and expanding healthcare infrastructure further contribute to market growth.

Market Overview

The inactivated vaccines market is experiencing robust growth, driven by various factors. The growing awareness of the benefits of vaccines in disease prevention and expanding government immunization programs are primary catalysts. The increasing global demand for vaccinations against infectious diseases like influenza, hepatitis, and polio continues to drive demand for safe and effective products. Inactivated vaccines, known for their strong safety profiles and shelf life, are preferred for pediatric and adult vaccination schedules. Technological advancements in vaccine production, coupled with increased public and private sector investment, are also supporting market growth.

Supportive government recommendations in both developed and developing countries, based on vaccine safety, stability, and efficacy, further contribute to market expansion. The expansion of healthcare systems, especially in emerging economies, also boosts vaccine demand. Considering the rising prevalence of communicable diseases, there is a high demand for preventive healthcare services, opening up new growth avenues for the market.

Segment Insights

• By vaccine type, the whole virus inactivated vaccines segment led the market, holding a major revenue share in 2024. The dominance of these vaccines stems from their higher safety profile than live vaccines.
• By disease indication, the polio segment dominated the market in 2024, driven by global polio eradication goals and strong immunization coverage. With the growing public health concerns, there is a strong emphasis on polio eradication, boosting the demand for inactivated vaccines.
• By age group, the pediatrics (0–18 years) segment led the inactivated vaccines market. There is a high demand for childhood immunizations, as children are more prone to infectious diseases.
• By end-user, the public immunization programs segment dominated the market in 2024, driven by government efforts and initiatives to provide mass immunization programs and accessible healthcare in many areas of the world.
• By distribution channel, the government supply contracts segment led the market in 2024, as they ensure widespread availability and timely intervention of inactivated vaccines. These contracts enable bulk procurement for thousands of public health distribution centers.

Regional Insights

Asia Pacific registered dominance in the inactivated vaccines market in 2024. This is mainly due to increased immunization programs, access to preventative healthcare services in countries like India and China, and high prevalence of infectious diseases. Governments around the region are making efforts to address public health concerns, and a growing focus on pandemic preparedness further contributes to market growth.

The market in the Middle East & Africa is expected to grow at the fastest rate during the forecast period. This is mainly due to the increasing prevalence of infectious diseases like polio and influenza. Governments around the region are investing heavily to develop novel vaccines to address emerging infectious diseases, supporting market growth.

Inactivated Vaccines Market Coverage

Recent Development

• In December 2024, WHO prequalified inactivated oral cholera vaccine EuvicholS. Approved as a ready to use, inactivated oral cholera vaccine, aiding global vaccination programs. (Source- https://extranet.who.int)

Inactivated Vaccines Market Players

• GSK plc 
• Bharat Biotech (Covaxin, Typbar)
• Sinovac Biotech Ltd.
• Sinopharm (CNBG)
• Serum Institute of India (SII)
• Pfizer Inc.
• Valneva SE
• Moderna, Inc. (expanding into inactivated pipeline)
• Biological E. Limited
• Panacea Biotec Ltd.
• Chumakov Institute of Poliomyelitis and Viral Encephalitides (Russia)
• IDT Biologika
• Emergent BioSolutions
• Novavax, Inc. (subunit but related pipeline)
• Incepta Vaccine Ltd. (Bangladesh)
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• Bio Farma (Indonesia)
• Bio Farma (Indonesia)
• Walvax Biotechnology Co., Ltd. (China)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6506

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344